Sugi Predict

Sugi Predict / Compounds / SCHEMBL2830293

SCHEMBL2830293

SCHEMBL2830293

CC(Oc1ccc(C#N)cc1)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.59
▸ PKM P14618 2/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CYP2C9 P11712 1/20 0.59
▸ CYP2C19 P33261 1/20 0.59
▸ SLC22A12 Q96S37 2/20 0.59
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ TDP1 Q9NUW8 1/20 0.54
▸ PPARG P37231 2/20 0.47
▸ PPARA Q07869 2/20 0.47
▸ MAPT P10636 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ MMP2 P08253 2/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.46
▸ MMP3 P08254 1/20 0.46
▸ PARP15 Q460N3 1/20 0.45
▸ PARP10 Q53GL7 1/20 0.45
▸ PARP2 Q9UGN5 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21057155 1.00 GAA (0.59) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL7841233 0.95 SLC22A12 (0.55) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL7841235 0.95 SLC22A12 (0.55) GAAPKMCYP1A2CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL10367203 0.94 SLC22A12 (0.54) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL4262556 0.84 CYP1A2 (0.77) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL11707781 0.84 GAA (0.49) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL4748762 0.83 GAA (0.48) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL30575141 0.83 TAS1R3 (0.65) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL667009 0.83 GAA (0.48) GAAPKMCYP1A2CYP2C9CYP2C19
SCHEMBL25280212 0.83 MAPT (0.61) GAASMN1; SMN2MAPTALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3723745-A1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2020-10-21 — — EP claimed
CN-111587109-A Phenoxy acids for the treatment of neuromuscular disorders NMD制药股份公司 2020-08-25 — — CN claimed
WO-2019115777-A1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2019-06-20 — — WO claimed
US-20190183834-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA A/S (DK) 2019-06-20 — — US claimed
US-20190183833-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA APS 2019-06-20 — — US claimed
CN-119823119-A Pol theta inhibitor and preparation method, pharmaceutical composition and application thereof 中国药科大学 2025-04-15 — — CN disclosed
CN-110997627-B Cyst amide derivatives 亥姆霍兹感染研究中心有限公司 2023-10-10 — — CN disclosed
US-11730714-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2023-08-22 — — US disclosed
US-11147788-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2021-10-19 — — US disclosed
US-11034648-B2 Cystobactamide derivatives HELMHOLTZ-ZENTRUM FÜR (DE) 2021-06-15 — — US disclosed
EP-3723745-A1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2020-10-21 — — EP disclosed
CN-111587109-A Phenoxy acids for the treatment of neuromuscular disorders NMD制药股份公司 2020-08-25 — — CN disclosed
EP-3672937-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-07-01 — — EP disclosed
US-20200190020-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-06-18 — — US disclosed
CN-110997627-A Novel cystobacter amide derivatives 亥姆霍兹感染研究中心有限公司 2020-04-10 — — CN disclosed
US-20190183833-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA APS 2019-06-20 — — US disclosed
WO-2019115777-A1 PHENOXY ACIDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2019-06-20 — — WO disclosed
US-20190183834-A1 Compounds For The Treatment Of Neuromuscular Disorders NMD PHARMA A/S (DK) 2019-06-20 — — US disclosed
WO-2019038405-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2019-02-28 — — WO disclosed
US-20100168101-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2010-07-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11034648-B2 Cystobactamide derivatives CTH, CBS, SLC7A11 GAA 2916/4885PKM 1605/4885CYP1A2 1931/4885
US-11730714-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 GAA 2463/4885PKM 3649/4885CYP1A2 4681/4885
US-20190183834-A1 Compounds For The Treatment Of Neuromuscular Disorders RYR1, CACNB1, RYR2 GAA 2463/4885PKM 3649/4885CYP1A2 4681/4885
US-11147788-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, RYR2 GAA 2463/4885PKM 3649/4885CYP1A2 4681/4885
US-20200190020-A1 NOVEL CYSTOBACTAMIDE DERIVATIVES CTH, CBS, SLC7A11 GAA 2558/4885PKM 1381/4885CYP1A2 2541/4885
US-20190183833-A1 Compounds For The Treatment Of Neuromuscular Disorders RYR1, CACNB1, RYR2 GAA 2463/4885PKM 3649/4885CYP1A2 4681/4885
US-20100168101-A1 OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) PTPRO, PTPRE, PTPRZ1 GAA 2377/4885PKM 1771/4885CYP1A2 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.